Cargando…

Correction to: GP2015: An Etanercept Biosimilar

Detalles Bibliográficos
Autor principal:	Deeks, Emma D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182453/ https://www.ncbi.nlm.nih.gov/pubmed/30069733 http://dx.doi.org/10.1007/s40259-018-0296-z

Ejemplares similares

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
por: Carballo, Nuria, et al.
Publicado: (2022)

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
por: von Richter, Oliver, et al.
Publicado: (2016)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
por: Matucci-Cerinic, Marco, et al.
Publicado: (2018)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Correction: Preparing for the incoming wave of biosimilars in oncology
Publicado: (2018)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Correction to: The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages
por: Shirmohammadi, Elnaz, et al.
Publicado: (2020)

Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
por: Chen, Fangfang, et al.
Publicado: (2023)

Correction to: MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2022)

Correction to: Odevixibat: First Approval
por: Deeks, Emma D.
Publicado: (2021)

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2016)

Correction to: Sarecycline: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Correction to: Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study
por: Gerdes, S., et al.
Publicado: (2017)

Correction to: Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2019)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Correction to: Tapentadol Prolonged Release: A Review in Pain Management
por: Deeks, Emma D.
Publicado: (2019)

Correction to: Abrocitinib: First Approval
por: Deeks, Emma D., et al.
Publicado: (2022)

Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
por: Deeks, Emma D.
Publicado: (2019)

Correction to: To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Hassett, Brian, et al.
Publicado: (2018)

Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2018)

Correction to: Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p8it80aoni2a6vdv96f2nh5ksr